Fondaparinux to Prevent Thrombotic Complications and Graft Failure in Patients Undergoing Coronary Artery Bypass Graft Surgery: The Fonda CABG Study

NCT00474591 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

100

Enrollment

OTHER

Sponsor class

Conditions

Coronary Bypass Graft Failure/Occlusion

Interventions

DRUG: Fondaparinux

Sponsor

Hamilton Health Sciences Corporation

Collaborators

[object Object]